Navigation Links
Brigham and Women's Hospital researchers initiate major cardiovascular inflammation reduction trial
Date:8/22/2012

Boston, MA Fifteen years ago, researchers at Brigham and Women's Hospital (BWH) reported that C-reactive protein (CRP), a biomarker of inflammation found in the blood, was as powerful a tool to predict future heart attack and stroke as was total cholesterol. Today, the same research group announces the launch of a new randomized clinical trial, funded by The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), to determine whether lowering inflammation with a common anti-inflammatory drug will in turn reduce rates of recurrent heart attack, stroke, and cardiovascular death in high risk patients who have already suffered a prior heart attack.

"We are exceptionally grateful to the National Heart, Lung, and Blood Institute for funding the Cardiovascular Inflammation Reduction Trial" said Paul M Ridker, MD, principal investigator for the new trial and Director of the Center for Cardiovascular Disease Prevention at BWH in Boston. "We believe that the concept of reducing inflammation has enormous potential as a new method to reduce the burden of heart attack and stroke for our patients."

The Cardiovascular Inflammation Reduction Trial (CIRT) will test whether low-dose methotrexate [Trexall (methotrexate tablets USP)], an inexpensive drug widely used to treat rheumatoid arthritis, can reduce the rates of recurrent cardiovascular events among patients with a prior heart attack who also have diabetes or metabolic syndrome, conditions known to be associated with a heightened inflammatory response. Such individuals are at very high risk for second and third cardiac events which are often life-threatening, despite all currently available interventions including aggressive cholesterol reduction with statin therapy.

Researchers will enroll 7,000 patients from up to 400 clinical sites across the United States and Canada. All patients will receive aggressive standard of care and in addition, half will receive low-dose methotrexate (target dose of 20 mg/week) while the other half will receive a placebo. All participants will be followed for 3 to 5 years for recurrent major cardiovascular events.

"Prior research suggests that inflammation plays a critical role in heart attack and stroke," said Gary H. Gibbons, M.D., director of the NHLBI, which is funding the study. "This trial promises to offer evidence about the relative importance of inflammation and may lead to new treatment paradigms for millions of people with cardiovascular disease," added Dr. Gibbons.

"This new study is the end-game for more than fifteen years of research by investigators worldwide demonstrating that inflammation is a central part of the process that leads to heart attack and stroke," Dr. Ridker said. "Whether or not reducing that inflammation can benefit our patients is unknown, but a positive finding in this trial has the potential to dramatically reshape how we think about and treat heart disease."

The concept of treating inflammation to prevent chronic disease has a long history at BWH in Boston. In addition to Dr. Ridker's work, BWH researchers Dr. Peter Libby, chief of the Division of Cardiology, and Dr. Michael Gimbrone, director of Center for Excellence in Vascular Biology, performed ground-breaking work investigating basic mechanisms of inflammation in heart disease. Additionally, low-dose methotrexate as a treatment for rheumatoid arthritis was pioneered at BWH by Dr. Michael Weinblatt and others in the 1980's.

Screening will begin in January 2013 with patient recruitment in March, 2013. Physicians and clinical sites interested in CIRT can obtain further information at www.theCIRT.org.


'/>"/>
Contact: Lori J. Schroth
ljschroth@partners.org
617-534-1604
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Predictors identified for rehospitalization among post-acute stroke patients
3. More Smog Might Mean More Hospitalizations
4. After Hospitalization, Men More Likely to Show Up in ER
5. Choosing the right hospital may save your babys life
6. Heart Attack Survival Varies Widely Among Hospitals, Study Finds
7. In Some Brain Bleeds, Patients Do Better at High-Volume Hospitals
8. Rate of Hospitalizations for Stroke Has Declined in U.S.
9. Hospital readmission rates linked to availability of care, socioeconomics
10. Availability of Beds, Poverty Drive Costly Hospital Readmissions
11. Inhaled Steroids Lead to Big Drop in Asthma Deaths at Texas Hospital: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/22/2017)... ... 2017 , ... Branches, Inc. has been partnering with The Miami Foundation for ... its programs focused on providing opportunity to low-income families and breaking the cycle of ... of $15,000 to support its , Climb to College & Career initiative which focuses ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many physicians are unfamiliar ... integrate basic science with clinical practice. Now, however, a timely review has been published ... insight into the etiology of NeuP and educating preclinical scientists on its diagnosis and ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., a leading ... eBook titled “ 5 Questions to Ask Before Entering the Maze of Genetic ... Test Evaluation (GTE) team, the book explores the various types of the more ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology: